FIT vs Cologuard: What Separates the Two Stool Tests

What Each Test Actually Measures

The fit test, formally the fecal immunochemical test, uses an antibody that reacts specifically to human hemoglobin to look for hidden blood in a stool sample 1Ref 1Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.That FIT uses an antibody specific to human hemoglobin to detect hidden blood, with pooled sensitivity of about 79% and specificity of about 94% for colorectal cancer — used to describe what FIT measures and how accurate it is.. Cologuard runs that same blood-detecting chemistry alongside a DNA analysis, screening for genetic and epigenetic markers linked to colorectal cancer and precancerous polyps — its stool-DNA methylation and hemoglobin markers are built to pick up early signals that bleeding alone might miss 2Ref 2Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. (2014).Multitarget stool DNA testing for colorectal-cancer screening.The pivotal study behind Cologuard's FDA approval, showing higher single-test sensitivity for colorectal cancer than FIT but lower specificity — used to describe the original Cologuard mechanism and its accuracy trade-off against FIT..

Both are mailed to a lab from a sample collected at home, and neither requires the bowel prep or sedation a colonoscopy does. What differs is the biology each one is actually built to detect, which is also where their accuracy numbers start to diverge.

How Accurate Is Each Test at Actually Finding Cancer?

A meta-analysis of FIT studies found the test correctly identified about 79% of colorectal cancers in a screening population and correctly cleared about 94% of people who did not have cancer 1Ref 1Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.That FIT uses an antibody specific to human hemoglobin to detect hidden blood, with pooled sensitivity of about 79% and specificity of about 94% for colorectal cancer — used to describe what FIT measures and how accurate it is.. The pivotal study behind Cologuard's FDA approval found the stool-DNA test had higher single-test sensitivity for finding cancer than FIT, but lower specificity — meaning it catches more cancers per round while also flagging more people who ultimately turn out not to have one 2Ref 2Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. (2014).Multitarget stool DNA testing for colorectal-cancer screening.The pivotal study behind Cologuard's FDA approval, showing higher single-test sensitivity for colorectal cancer than FIT but lower specificity — used to describe the original Cologuard mechanism and its accuracy trade-off against FIT.. The newest version of Cologuard, studied in a large trial called BLUE-C, reported the same general pattern against FIT in an average-risk screening population: better at finding cancer, at the cost of more false alarms 3Ref 3Imperiale TF, Porter K, Zella J, et al. (BLUE-C Study Investigators) (2024).Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.The BLUE-C trial of the current-generation Cologuard test, reporting the same general sensitivity-for-specificity trade-off against FIT in an average-risk population — used for the current-generation Cologuard performance claim..

The fuller answer to how accurate is cologuard across different risk groups and age bands goes beyond a single head-to-head with FIT, but the trade-off itself — more sensitivity, less specificity — has held across both the original and the current-generation test.

What a Positive Result Actually Means for Either Test

A positive FIT or a positive Cologuard is not a cancer diagnosis. It means blood or abnormal DNA markers turned up in the stool sample, and the next step for either result is the same: a colonoscopy to find out why 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test (FIT or Cologuard) is covered as screening rather than diagnostic — used to explain what happens, and what it costs, after either test comes back positive.. Medicare and most private insurers cover that follow-up colonoscopy as a screening exam rather than a diagnostic one, specifically because the positive stool test is what triggered it 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test (FIT or Cologuard) is covered as screening rather than diagnostic — used to explain what happens, and what it costs, after either test comes back positive..

That follow-up step is identical no matter which test flagged it, which means the real difference between FIT and Cologuard isn't what happens after a positive result. It's how often a false positive happens in the first place, and how the two tests differ on cologuard cost and FIT cost long before either one ever comes back positive.

Medicaid adds its own layer of variation on top of that no-cost rule: coverage and cost-sharing for colorectal cancer screening differ from state to state under Medicaid, even though the underlying screening recommendation is federal and identical everywhere 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test (FIT or Cologuard) is covered as screening rather than diagnostic — used to explain what happens, and what it costs, after either test comes back positive.. Someone covered by Medicaid should not assume either test is automatically free without checking that state's own program directly.

How Often Each Test Needs Repeating

FIT is designed to be used every single year, and that yearly cadence is baked into its accuracy numbers: a single missed cancer in one year's sample gets another chance to be caught twelve months later 5Ref 5Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing (Cologuard) and CT colonography as second-tier — used to explain the difference in how often each test is meant to be repeated.. That yearly cadence rests on what's sometimes called the annual FIT interval evidence — modeling that shows repeated testing over years outperforms any single round's accuracy in isolation.

Cologuard is used far less often, which shifts more of the entire screening burden onto that one sample being right. Professional guidelines reflect that difference directly: annual FIT and colonoscopy every ten years rank as first-tier screening options, with Cologuard and CT colonography ranked second-tier 5Ref 5Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing (Cologuard) and CT colonography as second-tier — used to explain the difference in how often each test is meant to be repeated. — not because Cologuard is unreliable, but because a program repeated every year has more chances to catch something a single, less-frequent round might miss.

The Real Trade-Off: More Cancers Caught vs. Fewer False Alarms

The honest comparison isn't which test is more accurate in the abstract — it's which failure mode matters more to a given person. Cologuard tends to catch more cancers in the single round it's used 3Ref 3Imperiale TF, Porter K, Zella J, et al. (BLUE-C Study Investigators) (2024).Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.The BLUE-C trial of the current-generation Cologuard test, reporting the same general sensitivity-for-specificity trade-off against FIT in an average-risk population — used for the current-generation Cologuard performance claim., but it also flags more people who don't have cancer, which means more referrals for a colonoscopy that ultimately finds nothing wrong. FIT catches somewhat fewer cancers in any single round 1Ref 1Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.That FIT uses an antibody specific to human hemoglobin to detect hidden blood, with pooled sensitivity of about 79% and specificity of about 94% for colorectal cancer — used to describe what FIT measures and how accurate it is., but produces fewer false alarms, and it's designed to make up that difference through yearly repetition rather than single-test power 5Ref 5Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing (Cologuard) and CT colonography as second-tier — used to explain the difference in how often each test is meant to be repeated..

Neither trade-off is free. More false positives means more people going through an unnecessary colonoscopy, with its own small procedural risks and its own bill if it gets coded as diagnostic rather than screening. Fewer false positives, bought through a less sensitive single test, only works if the person actually returns for it again every year without fail.

Which One Actually Gets Used Matters More Than Which One 'Wins'

The test that actually gets repeated, year after year, outperforms the test with the best single-round numbers left sitting in a drawer. FIT asks for a fresh sample every year — a small task, repeated often. Cologuard asks for far less frequent action, but a bigger single commitment each time it comes due. Consistency, not raw single-round sensitivity, is what actually determines how well either program protects someone over a decade of screening 5Ref 5Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing (Cologuard) and CT colonography as second-tier — used to explain the difference in how often each test is meant to be repeated..

How Cologuard fares in a direct cologuard vs colonoscopy comparison is a related but separate question from how it fares against FIT, which is what this page has covered. For most people, the right test is simply the one they will reliably repeat, not the one with the marginally better single-test numbers on paper.

A doctor weighing which test to recommend is often weighing exactly that: not which test wins on a spec sheet, but which one a specific person is actually likely to complete on schedule, year after year or round after round, since a screening program only works if someone stays in it.